Skip to content

Study · Non-randomized trial · 1994

1 result

[Pharmacological possibilities in treatment hypoacusis in children].

Pruszewicz A, Obrebowski A, Woźnica B, Swidziński P

Otolaryngologia polska = The Polish otolaryngology1 Jan 1994

PMID7970765 (opens in a new tab)PepBankPUB-07970765
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with deep sensorineural hypoacusis and a central component, hearing examination results improved in 36% after Cerebrolysin treatment.

    In plain wordsIn children with deep hearing loss and a central component, hearing examination results improved in 36% after Cerebrolysin treatment.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseImprovement in hearing examination results
    Study

    n: not reported in source

    Outcome group
    Sensory perception · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Improvement
    36%
    Cerebrolysin-treated first group

    Source sentences

    Summary
    The improvement in examination results in the first group was observed in 36%.
    3 context sentences
    Summary · context
    The first group consisted of children with deep sensorineural hypoacusis together with central component of hypoacusis, whereas the second group included children with sudden occurrence of hypoacusis or detorioration of diminished hearing ability.
    Summary · context
    The first group received a treatment with a drug stimulating the function of central nervous system, Cerebrolysin (Minden, D), whereas the other one underwent typical therapy applied in case of sudden deafness (mannitol, hydrocortison, vitamins, enzymes).
    Summary · context
    Both the groups were subjected to objective examination of hearing before and after the treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.